RESUMO
BACKGROUND: Chagas disease has become a challenge for non-endemic countries since population mobility has increased in recent years and it has spread to these regions. In order to prevent vertical transmission and improve the prognosis of the disease, it is important to make an early diagnosis. And to develop strategies that improve access to diagnosis, it is important to know the factors that most influence the decision of the population to know their serological status. For this reason, this study uses Andersen's Behavioural Model and its proposed strategies to explore the health behaviours of Bolivian population. METHODS: Twenty-three interviews, two focus groups, and two triangular groups were performed with Bolivian men and women, involving a total of 39 participants. In addition, four interviews were conducted with key informants in contact with Bolivian population to delve into possible strategies to improve the Chagas diagnosis. RESULTS: The most relevant facts for the decision to being diagnosed pointed out by participants were having relatives who were sick or deceased from Chagas disease or, for men, having their pregnant wife with a positive result. After living in Spain more than ten years, population at risk no longer feels identified with their former rural origin and the vector. Moreover, their knowledge and awareness about diagnosis and treatment still remains low, especially in younger people. Limitations on access to healthcare professionals and services were also mentioned, and proposed strategies focused on eliminating these barriers and educating the population in preventive behaviours. CONCLUSIONS: Based on Andersen's Behavioural Model, the results obtained regarding the factors that most influence the decision to carry out Chagas diagnosis provide information that could help to develop strategies to improve access to health services and modify health behaviours related to Chagas screening.
Assuntos
Doença de Chagas/etnologia , Comportamentos Relacionados com a Saúde , Conhecimentos, Atitudes e Prática em Saúde , Adulto , Bolívia/etnologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Teóricos , Espanha/epidemiologiaRESUMO
Chagas disease (CD) is a vector-borne parasitic disease endemic to Latin America. The US has established populations of vectors, parasites, and animal hosts, but because of the low frequency of locally acquired human infections CD is not classified as endemic there. I present a narrative review of the literature of autochthonous cases of CD in the US and analyze it with a co-productionist framework focused on material politics. I underscore the need for an ethnographic approach to the category of endemicity as not only an issue of knowledge and evidence but also as a practiced condition infused with power.
Assuntos
Doença de Chagas , Idoso , Antropologia Médica , Doença de Chagas/etnologia , Doença de Chagas/transmissão , Doenças Endêmicas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Política , Estados Unidos/etnologiaRESUMO
Disparities in control mechanisms to prevent the spread of Chagas disease in Switzerland raise questions about the process of its recognition as a public health problem, particularly as it concerns migrant populations. With a focus on congenital screening practices, I explore the way in which health care providers experience, problematize and respond to the disease, acting as key agents not only in the provision of care but also in the recognition of Chagas disease as a problem that needs to be addressed. Such an approach contributes to the understanding of processes of public health agenda creation around neglected tropical diseases in non-endemic countries.
Assuntos
Doença de Chagas , Acessibilidade aos Serviços de Saúde , Complicações Parasitárias na Gravidez , Diagnóstico Pré-Natal , Adulto , Antropologia Médica , Doença de Chagas/congênito , Doença de Chagas/diagnóstico , Doença de Chagas/etnologia , Doença de Chagas/terapia , Emigrantes e Imigrantes , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Doenças Negligenciadas , Gravidez , Complicações Parasitárias na Gravidez/diagnóstico , Complicações Parasitárias na Gravidez/etnologia , Complicações Parasitárias na Gravidez/terapia , Saúde Pública , SuíçaRESUMO
Mexican immigrants are affected by Chagas disease (CD) in California. It is through the representation of Chagas as a rare disease that participants make sense of the disease. A positive diagnosis has meant the disruption of patients' sense of normality and self-image, as well as their memories of homeland both reproducing and challenging hegemonic and stigmatized ideas of the disease associated with rurality and poverty. Access to treatment and medical care was the major coping mechanism. Health programs on CD should consider the emotional and social impact of the disease on people's self-perceptions to develop better medical care and prevention.
Assuntos
Doença de Chagas , Emigrantes e Imigrantes , Adulto , Antropologia Médica , California , Doença de Chagas/etnologia , Doença de Chagas/psicologia , Doença de Chagas/terapia , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , México/etnologia , Pobreza , Pesquisa Qualitativa , População RuralRESUMO
Chagas disease is the neglected tropical disease of greatest public health impact in the United States, where it affects over 300,000 people. Diverse barriers limit healthcare access for affected people; fewer than 1% have obtained testing or treatment. We interviewed 50 people with Chagas disease in Los Angeles, California, and administered a cultural consensus analysis questionnaire. Participants were asked about their experiences and perceptions of Chagas disease, access to healthcare, and strategies for coping with the disease. In participants' narratives, the physical and emotional impacts of the disease were closely interwoven. Participant explanatory models highlight difficulties in accessing care, despite a desire for biomedical treatment. Obtaining testing and treatment for Chagas disease poses substantial challenges for US patients.
Assuntos
Doença de Chagas , Adulto , Antropologia Médica , América Central/etnologia , Doença de Chagas/etnologia , Doença de Chagas/psicologia , Doença de Chagas/terapia , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Los Angeles , Masculino , México/etnologia , Pessoa de Meia-IdadeRESUMO
In this article, we explore relationships between risk and emotions among Bolivian women living with Chagas disease, and the implications of this for their diagnosis and treatment in Catalonia, Spain. Here, risk is a social phenomenon, while emotions are conceived as embedded in the sociocultural and relational world. Emotions play key risk-related roles as both a cause and consequence of Chagas disease, are the basis of health practices, and allow us to link risk to wider social inequalities. The way we conceive emotions is crucial both theorically and practically.
Assuntos
Doença de Chagas , Aceitação pelo Paciente de Cuidados de Saúde , Antropologia Médica , Bolívia/etnologia , Doença de Chagas/etnologia , Doença de Chagas/psicologia , Emigrantes e Imigrantes/psicologia , Feminino , Humanos , Aceitação pelo Paciente de Cuidados de Saúde/etnologia , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Fatores de RiscoRESUMO
BACKGROUND: Trypanosoma cruzi has a high genetic and biological diversity and has been subdivided into seven genetic lineages, named TcI-TcVI and TcBat. DTUs TcI-TcII-TcV and TcVI are agents of ChD in different regions of Latin America. Due to population movements, the disease is an emergent global public health problem. Thus, the aim of this study was to quantify the parasitic load and identify the presence of T. cruzi DTUs in 101 Latin American immigrants with chronic ChD, residing in Barcelona, Spain. METHODOLOGY / PRINCIPAL FINDINGS: 5ml of peripheral blood were collected in guanidine/EDTA from each patient for DNA extraction, quantification of the parasitic load and genotyping. A great variation of the parasitic load of the patients was verified: from 0.001 to 22.2 T. cruzi DNA (fg) / Blood DNA (ng). In patients from Bolivia the parasitic load was 3.76±4.43 T. cruzi DNA (fg) / Blood DNA (ng) (mean ± SD), in patients of other countries was 0.95±1.38 T. cruzi DNA (fg) / Blood DNA (ng). No statistically significant difference was observed in the parasitic load between patients with the indeterminate and cardiac forms of ChD (p = 0,57). Parasite genotyping was performed by multilocus conventional PCR. In patients from Bolivia there was a nearly equal prevalence of DTUs TcV (27/77), TcII/TcV/TcVI (26/77), and TcII/TcVI (22/77). TcVI was detected in only 2 samples (2/77). A higher prevalence of TcII/TcVI (19/24) was verified in patients of other countries, with low prevalence of TcII/TcV/TcVI (4/24) and TcV (1/24). CONCLUSIONS/SIGNIFICANCE: In this study, low/medium parasitic load was found in all patients evaluated. Our data corroborate previous conclusions indicating that patients from the Bolivia, living in Spain, are predominantly infected by TcV, and TcVI DTUs. On the other hand, in Non-Bolivians patients TcII/TcVI predominated. Surprisingly, in our cohort of 101 patients no infection by TcI DTU was observed.
Assuntos
Doença de Chagas/etnologia , Doença de Chagas/parasitologia , DNA de Protozoário/genética , Emigrantes e Imigrantes , Trypanosoma cruzi/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Bolívia/etnologia , Feminino , Variação Genética , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Tipagem Molecular , Carga Parasitária , Análise de Sequência de DNA , Espanha/epidemiologia , Trypanosoma cruzi/isolamento & purificação , Adulto JovemRESUMO
Chagas disease (CHD) has become a challenge in Spain due to the high prevalence of immigrants coming from endemic areas. One of the main difficulties for its control and elimination is its underdiagnosis. The identification and integral treatment of CHD are key to increasing rates of diagnosis, overcoming psycho-social barriers and avoiding CHD progression. Community interventions with in situ screening have proven to be a useful tool in detecting CHD among those with difficulties accessing health services. To determine the underdiagnosis rate of the population most susceptible to CHD among those attending two different Bolivian cultural events celebrated in Barcelona; to describe the sociodemographic characteristics of the people screened; and to analyse the results of the screening. The community interventions were carried out at two Bolivian cultural events held in Barcelona in 2017. Participants were recruited through community health agents. A questionnaire was given to determine the participants' prior knowledge of CHD. In situ screening was offered to those who had not previously been screened. Those who did not wish to be screened were asked for the reason behind their decision. Results were gathered in a database and statistical analyses were performed using STATA v14. 635 interviews were carried out. 95% of the subjects reported prior knowledge of CHD. 271 subjects were screened: 71.2% women and 28.8% men, of whom 87.8% were of Bolivian origin. The prevalence of CHD was 8.9%. Community health interventions with in situ screening are essential to facilitating access to diagnosis.
Assuntos
Doença de Chagas , Bolívia/etnologia , Doença de Chagas/diagnóstico , Doença de Chagas/epidemiologia , Doença de Chagas/etnologia , Serviços de Saúde Comunitária , Emigrantes e Imigrantes , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Masculino , Programas de Rastreamento , Prevalência , EspanhaRESUMO
La enfermedad de Chagas afecta aproximadamente a 10 millones de personas en Sudamérica y 1,5 millones en la Argentina. La transmisión congénita es la más importante en áreas urbanas. Existen dos drogas aprobadas para el tratamiento: nifurtimox (Laboratorios Bayer) y benznidazol (BNZ) (Laboratorios Roche, LAFEPE y Elea) que fueron desarrolladas hace más de 40 años y cuya farmacología y metabolismo en humanos han sido poco estudiados. La información disponible es virtualmente inexistente en niños y mujeres embarazadas. Se busca aportar estudios sistemáticos hacia una farmacoterapéutica racional en niños ya que empíricamente ha demostrado gran efectividad. Se desarrollaron métodos bioanalíticos aplicables a matrices biológicas como plasma, orina y leche materna para las drogas madres y la identificación de metabolitos en muestras de pacientes bajo terapéutica. La farmacocinética poblacional pediátrica descripta aquí para BNZ es concluyente respecto de sus diferencias con la farmacocinética en adultos. Se identificaron tres compuestos presentados como metabolitos del BNZ. La transferencia de dicho fármaco a la leche materna no supone riesgo para el lactante. Estos resultados brindan información para mejorar los protocolos de tratamiento existentes buscando una farmacoterapéutica adaptada a la edad y un uso más seguro de los fármacos en niños y eventualmente en adultos.
Chagas disease affects approximately 10 million people in South America and 1.5 million in Argentina. Congenital transmission is most important in urban areas. There are two drugs approved for treatment: nifurtimox (Bayer) and benznidazole (BNZ) (Roche, LAFEPE, Elea),developed more than 40 years ago. Their pharmacology and metabolism in humans have been seldom studied. The information available on children and pregnant women is virtually non-existent. The aim of this study is to provide systematic studies towards a rational pharmacotherapeutic sin children, which has been empirically proven to be highly effective. Bioanalytical methods were developed for plasma, urine and breast milk for parent drugs and for the identification of their metabolites in samples of patients under treatment. The pediatric population pharmacokinetics described here for BNZ is conclusive about their differences from adult pharmacokinetics. Three compounds presented as BNZ metabolites were identified. The transfer of this drug to the breast milk does not present a risk to the infant. These evidences offer information to improve the existing treatment protocols, seeking a pharmacotherapy adapted to the age and a safer use of the drugs in children and eventually in adults.
A doença de Chagas afeta aproximadamente 10 milhões de pessoas na América do Sul e 1,5 milhão na Argentina. A transmissão congênita é a mais importante em áreas urbanas. Existem dois medicamentos aprovados para o tratamento: nifurtimox (Laboratórios Bayer) e benznidazol (BNZ) (Laboratórios Roche, LAFEPE e Elea), desenvolvidas há mais de 40 anos, e sua farmacologia e seu metabolismo em humanos têm sido pouco estudados. A informação disponível é praticamente inexistente em crianças e mulheres grávidas. O objetivo é fornecer estudos sistemáticos para uma farmacoterapêutica racional em crianças visto que foram comprovadas empiricamente como sendo altamente eficazes. Métodos bioanalíticos aplicáveis a matrizes biológicas como plasma, urina e leite materno para fármacos-mãe e para a identificação de metabólitos em amostras de pacientes em tratamento terapêutico foram desenvolvidos. A farmacocinética da população pediátrica aqui descrita para BNZ é conclusiva em relação às suas diferenças com a farmacocinética de adultos. Três compostos apresentados como metabólitos do BNZ foram identificados. A transferência do referido medicamento para o leite materno não representa risco para o lactente. Essas evidências oferecem informações para melhorar os protocolos de tratamento existentes, buscando uma farmacoterapia adaptada à idade e um uso mais seguro dos medicamentos em crianças e eventualmente em adultos.
Assuntos
Humanos , Masculino , Feminino , Toxicologia , Doença de Chagas/diagnóstico , Doença de Chagas/tratamento farmacológico , Lactação/efeitos dos fármacos , Doença de Chagas/etiologia , Doença de Chagas/etnologia , Ações Farmacológicas , Efeitos Colaterais Metabólicos de Drogas e SubstânciasRESUMO
BACKGROUND: Chagas disease is a protozoan infection caused by Trypanosoma cruzi. The disease has a chronic course in which 20-30% of the patients would develop progressive damage to the cardiovascular system and the gastrointestinal tube. We are still unable to predict who will develop end-organ damage but there are some acquired and genetic risk factors already known. RESULTS: We reviewed data from 833 patients with serologically confirmed Chagas disease in this retrospective study. Patients were classified as siblings or non-siblings (controls) and the results of pre-treatment blood PCR assay, end-organ damage (cardiac and/or gastrointestinal), and the presence of delayed type hypersensitivity (DTH) skin involvement in patients treated with benznidazole were analyzed. Siblings were grouped by family and we randomly generated groups of 2 or 3 persons with the remaining controls. We classified the results of each variable as concordant or discordant and compared the concordance in these results among the sibling groups with that among control groups. We identified 71 groups of siblings and randomly generated 299 groups of non-related patients. Pre-treatment blood PCR concordance was significantly higher (19%) among siblings compared to controls (P = 0.02), probably due to a higher frequency in pre-treatment positive results. No other statistically significant differences were found. CONCLUSIONS: A significant difference was found in the concordance of pre-treatment blood PCR for T. cruzi among siblings compared to non-related controls.
Assuntos
Doença de Chagas/etnologia , Doença de Chagas/genética , Irmãos , Adulto , Bolívia , Cardiomiopatia Chagásica/diagnóstico , Cardiomiopatia Chagásica/etiologia , Doença de Chagas/complicações , Doença Crônica , Feminino , Gastroenteropatias/diagnóstico , Gastroenteropatias/parasitologia , Humanos , Masculino , Estudos Retrospectivos , Fatores de Risco , Tripanossomicidas/uso terapêutico , Trypanosoma cruziRESUMO
BACKGROUND: The social determinants of health (SDHs) condition disease distribution and the ways they are handled. Socio-economic inequalities are closely linked to the occurrence of neglected tropical diseases, but empirical support is limited in the case of Chagas disease, caused by the protozoan Trypanosoma cruzi. Herein we assessed the relationship between key structural SDHs and the risk of T. cruzi vector-borne transmission in rural communities of the Argentine Chaco occupied by creoles and an indigenous group (Qom). We used multiple correspondence analysis to quantify the household-level socio-economic position (social vulnerability and assets indices), access to health and sanitation services, and domestic host availability. We identified the most vulnerable population subgroups by comparing their demographic profiles, mobility patterns and distribution of these summary indices, then assessed their spatial correlation and household-level effects on vector domiciliary indices as transmission risk surrogates. RESULTS: Qom households had higher social vulnerability and fewer assets than creoles, as did local movers and migrant households compared with non-movers. We found significantly positive effects of social vulnerability and domestic host availability on infected Triatoma infestans abundance, after adjusting for ethnicity. Access to health and sanitation services had no effect on transmission risk. Only social vulnerability displayed significant global spatial autocorrelation up to 1 km. A hotspot of infected vectors overlapped with an aggregation of most vulnerable households. CONCLUSIONS: This synthetic approach to assess socio-economic related inequalities in transmission risk provides key information to guide targeted vector control actions, case detection and treatment of Chagas disease, towards sustainability of interventions and greater reduction of health inequalities.
Assuntos
Doença de Chagas/transmissão , Grupos Populacionais , Determinantes Sociais da Saúde/etnologia , Fatores Socioeconômicos , Adolescente , Adulto , Idoso , Animais , Argentina , Doença de Chagas/etnologia , Criança , Pré-Escolar , Características da Família , Feminino , Humanos , Controle de Insetos , Insetos Vetores/parasitologia , Masculino , Pessoa de Meia-Idade , Fatores de Risco , População Rural , Inquéritos e Questionários , Triatoma/parasitologia , Trypanosoma cruzi , Adulto JovemRESUMO
The WHO recommends screening of Latin American migrants for Chagas disease to reduce morbidity and mortality and increase the likelihood of eradicating the disease. The objective was to assess the feasibility and acceptability of a screening strategy in one Swiss canton. From February 2011 to September 2012, people attending six healthcare centres of different types were offered a rapid diagnostic test if they or their mother were of Latin American origin (or, at the blood donation centre, if they had travelled for ≥1 year in Latin America). In addition, testing was offered during events where Latin Americans gathered. In total, 1,010 people were tested, mainly originating from Brazil (24%), Ecuador (13%) and Chile (10%). 54% were born in Latin America, 15% had a Latin American mother, and 29% were travellers. The prevalence of Chagas disease was 2.3% among migrants (15.5% in the community testing) and 0% among travellers. The prevalence was 18.0%, 0.8%, 0.5% and 0% among Bolivians, Ecuadorians, Brazilians and other countries respectively. Predictors for Chagas disease were: born in Latin America (OR = infinite, p <0.001), Bolivian origin (OR = 95, 95% CI: 19–482, p <0.001), being tested in the community (OR = 56, 95% CI: 14–218, p <0.001), and age >35 years OR = 3.4, 95% CI: 1.1–10.5, p = 0.03). The prevalence of Chagas disease was much higher in people attending social events than healthcare centres, suggesting that observations based only on health facility data underestimate the real prevalence of Chagas disease. Screening in the community was well accepted and should be promoted to reach the population at highest risk.
Assuntos
Doença de Chagas/diagnóstico , Doença de Chagas/epidemiologia , Programas de Rastreamento/métodos , Migrantes/estatística & dados numéricos , Adolescente , Adulto , Idoso , Doença de Chagas/etnologia , Criança , Estudos de Viabilidade , Feminino , Humanos , América Latina/etnologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Prospectivos , Suíça/epidemiologia , Adulto JovemRESUMO
BACKGROUND: It is estimated that around 52,000 people live with Chagas in Spain, but only 10% have been diagnosed. Migrants from Bolivia bear the burden of Chagas infection in Spain. However, little is known about their current management of Chagas diagnosis and treatment patterns. This study aimed to assess the Chagas related disease perception and health behaviour of Bolivians living in Madrid. METHODS AND PRINCIPAL FINDINGS: For a first time, a cross-sectional survey about Chagas' knowledges and practices was carried out in Madrid, Spain. A total of 376 Bolivians were interviewed about their Chagas health-seeking behaviour. Differences between men and women were assessed Most of Bolivians living in Madrid have access to the public health services. 44% of Bolivians included in the survey had a Chagas screening test done. However, while women did their test for Chagas mostly at hospital (59.2%), men also used the community campaigns (17.5%) and blood banks (14.3%). The prevalence reported among Bolivians tested was 27.7%. Unfortunately, more than half of those reporting a positive test for Chagas did not begin or completed treatment. Only 45.7% of positives reported having had their children tested for Chagas. CONCLUSIONS: Despite the increase in the number of Chagas diagnoses done in Madrid, the number of Bolivians who tested positive and then started or completed treatment remains very low. The fact that most Bolivians' access to the health system is through the primary healthcare services should be considered for improving management of cases and follow-up of treatment adherence. Local and national protocol establishing guidelines for the screening and treatment of Chagas disease would help improving case detection and management at all levels of the healthcare system.
Assuntos
Doença de Chagas , Emigrantes e Imigrantes , Comportamentos Relacionados com a Saúde , Programas de Rastreamento , Adolescente , Adulto , Idoso , Bolívia , Doença de Chagas/diagnóstico , Doença de Chagas/epidemiologia , Doença de Chagas/etnologia , Doença de Chagas/terapia , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Prevalência , EspanhaRESUMO
Chagas disease is a neglected tropical disease; the only viable drugs are outdated and produce frequent side effects, and the overwhelming majority of cases are undiagnosed and untreated. Globally, people encounter numerous impediments to accessing biomedical treatment for Chagas disease. However, little is known about how people with Chagas disease manage their health outside the biomedical system. In this article, I discuss knowledge of ethnomedical treatments among marginalized patients in an endemic area of Bolivia. I interviewed 68 patients, 63 (93 percent) of whom had positive diagnoses for Chagas disease. Participants free listed 66 ethnomedical remedies either for Chagas disease (n = 39) or its cardiac symptoms. Participants stressed the accessibility of ethnomedical remedies in contrast to the multiple barriers to accessing biomedical treatment. Far from eroding in the face of globalization and sociopolitical marginalization, ethnomedical knowledge in the study area is dynamic and flexible, communicated through various channels.
Assuntos
Doença de Chagas , Cymbopogon , Ivermectina/uso terapêutico , Medicina Tradicional , Extratos Vegetais/uso terapêutico , Antropologia Médica , Bolívia/etnologia , Doença de Chagas/tratamento farmacológico , Doença de Chagas/etnologia , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Doenças NegligenciadasRESUMO
El objetivo del trabajo consistió en identificar la seroprevalencia de la infección por Trypanosoma cruzi en niños en edad escolar en localidades de las provincias de Salta y Chaco. Se trabajó en 44 escuelas de la ciudad de Salta, en parajes de San Carlos; en 10 escuelas de La Unión y en 7 escuelas de Taco Pozo. El trabajo tiene un diseño de corte transversal. La toma de muestra se realizó por punción capilar con equipos Serokit, y la confirmación de los casos seropositivos o dudosos por punción venosa, y obtención de suero, para realizar HAI y ELISA. Los casos seropositivos confirmados fueron tratados con Benznidazol® durante 60 días en dosis de 5-7mg/kg/ día. Para el análisis estadístico se elaboraron tablas con frecuencias absolutas y relativas. Se analizaron 17.884 escolares y se detectaron159 seropositivos, siendo la mayor seroprevalencia en la localidad de La Unión y la menor en la ciudad de Salta. Se aplicó tratamiento a 93 niños (71,54 %) de la ciudad y en el ámbito rural se trataron todos los casos. La vía de infección vectorial fue la de mayor predominio en las madres (64,47%). Se concluye que aunque la seroprevalencia fue menor en la ciudad de Salta que en las zonas rurales, es necesario continuar con la vigilancia.
The aim of this work was to identify seroprevalence of Trypanosoma cruzi infection in school-age children who live in localities from Salta and Chaco. This work was conducted in the following schools: 44 located in Salta city, 10 in La Unión, 7 in Taco Pozo, and several in rural spots around San Carlos town. The design was cross-sectional and the samples were taken by capillary punction with Serokit equipment. Seropositive cases were confirmed by HAI and ELISA performed on serum obtained by venous punction. Confirmed seropositive cases were treated with Benznidazol® for 60 days in doses of 5-7 mg/kg/day. Tables with absolute and relative frequencies were made for statistical analysis. It resulted that the number of school-aged children analyzed was 17,884, 159 being seropositive. The highest seroprevalence was detected in La Unión and the lowest in Salta city. Treatment was given to 93 children (71.54%) from Salta city, while every child was treated in rural areas. Infections in mothers was vector-borne mainly (64.47%). It can be concluded that even though seroprevalence was lower in the city of Salta than in rural areas, it is important to continue monitoring for Chagas disease.
O objetivo do trabalho consistiu em identificar a soroprevalência da infecção por Trypanosoma cruzi em crianças em idade escolar em localidades das províncias de Salta e de Chaco. O trabalho foi realizado em 44 escolas da cidade de Salta, em paragens de San Carlos; em 10 escolas de La Unión e em 7 escolas de Taco Pozo. O mesmo tem um desenho de corte transversal. Tomada de amostra: foi realizada por punção capilar com equipamentos Serokit e a confirmação dos casos soropositivos ou duvidoso por punção venosa e obtenção de soro, para realizar HAI e ELISA. Os casos soropositivos confirmados foram tratados com Benznidazole® durante 60 dias em doses de 5-7 mg/kg/dia. Para a análise estatística foram preparadas tabelas com frequências absolutas e relativas. Analisaram-se 17.884 crianças detectando 159 soropositivos, sendo a maior soroprevalência na cidade de La Unión e a menor na cidade de Salta. Aplicou-se o tratamento a 93 crianças, (71,54%) da cidade e na área rural se trataram todos os casos. A via de infecção vetorial foi a de maior predominância nas mães (64,47%). Conclui-se que embora a soroprevalência tenha sido menor na cidade de Salta do que nas áreas rurais, é necessário continuar com a vigilância.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Doença de Chagas/diagnóstico , Doença de Chagas/tratamento farmacológico , Doença de Chagas/etnologia , Prevalência , Doença de Chagas/classificação , ParasitologiaRESUMO
The objective of this study was to estimate the prevalence of Treponema pallidum, Trypanosoma cruzi and Human immunodeficiency virus 1 (HIV-1) in five Amerindian populations of Argentina. A retrospective study was conducted among 857 Amerindian populations (112 Kollas, 298 Mbyá-guaraníes, 79 Sagua Huarpes, 368 Wichis) from 2007 to 2010. Screening and confirmation of T. pallidum, T. cruzi and HIV-1 were performed. T. pallidum and T. cruzi infections were detected in all communities with an overall prevalence rate of 4.2% and 16.8%, respectively. Although HIV was not detected, syphilis and Chagas' disease represent a challenge for the health care system and the reinforcement of public health strategies is necessary considering the socioeconomic isolation of these populations.
El objetivo de este trabajo fue estimar la prevalencia de Treponema pallidum, Trypanosoma cruzi y virus de la inmunodeficiencia humana (HIV-1) en 5 comunidades originarias de Argentina. Para ello, se realizó un estudio retrospectivo en 857 individuos (112 kollas, 298 mbyá-guaraníes, 79 sagua huarpes, 368 wichis) desde el 2007 hasta el 2010. Se realizó el diagnóstico completo para T. pallidum, T. cruzi y HIV-1. En todas las comunidades se confirmaron infecciones por T. pallidum y T. cruzi con una prevalencia total del 4,2 y del 16,8%, respectivamente. Aunque no se detectó HIV-1, sífilis y Chagas, representan un desafío para el sistema de salud, teniendo que reforzarse las estrategias de salud pública teniendo en cuenta el aislamiento socio-económico que sufren estas poblaciones.
Assuntos
Humanos , Indígenas Sul-Americanos , Sífilis , Infecções por HIV , Doença de Chagas , Argentina , Treponema pallidum/isolamento & purificação , Trypanosoma cruzi/isolamento & purificação , Sífilis/etnologia , Sífilis/terapia , Infecções por HIV/etnologia , Infecções por HIV/terapia , Estudos Retrospectivos , HIV-1 , Doença de Chagas/etnologia , Doença de Chagas/terapiaRESUMO
The objective of this study was to estimate the prevalence of Treponema pallidum, Trypanosoma cruzi and Human immunodeficiency virus 1 (HIV-1) in five Amerindian populations of Argentina. A retrospective study was conducted among 857 Amerindian populations (112 Kollas, 298 Mbyá-guaraníes, 79 Sagua Huarpes, 368 Wichis) from 2007 to 2010. Screening and confirmation of T. pallidum, T. cruzi and HIV-1 were performed. T. pallidum and T. cruzi infections were detected in all communities with an overall prevalence rate of 4.2% and 16.8%, respectively. Although HIV was not detected, syphilis and Chagas' disease represent a challenge for the health care system and the reinforcement of public health strategies is necessary considering the socioeconomic isolation of these populations.
Assuntos
Doença de Chagas , Infecções por HIV , Indígenas Sul-Americanos , Sífilis , Argentina , Doença de Chagas/etnologia , Doença de Chagas/terapia , Infecções por HIV/etnologia , Infecções por HIV/terapia , HIV-1 , Humanos , Estudos Retrospectivos , Sífilis/etnologia , Sífilis/terapia , Treponema pallidum/isolamento & purificação , Trypanosoma cruzi/isolamento & purificaçãoRESUMO
Background: Up to half of patients with Chagas' disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment. Objectives: To verify the incidence and possible factors associated with the suspension of benznidazole treatment in a large cohort of patients. Methods: We included 2075 patients treated with benznidazole during the projects managed by the medical humanitarian organization Doctors Without Borders (Médecins Sans Frontières) in Bolivia from 2009 to 2013. Benznidazole treatment was provided two or three times per day for â¼60 days at 5-7.5 mg/kg/day. A multiple logistic regression model was developed to evaluate the factors associated with permanent suspension of benznidazole treatment. Results: Permanent benznidazole treatment suspension occurred in 211 patients (10.2%) and the average time until permanent treatment suspension was 23 days. Multifactorial analysis revealed that female sex (adjusted OR = 1.70), moderate ADRs (adjusted OR = 10.57), mild ADRs (adjusted OR = 1.69) and skin disorders (adjusted OR = 4.18) were significantly associated with the permanent suspension of benznidazole treatment. Women with mild or moderate skin ADRs presented a probability of treatment interruption of 18.6% and 59.0%, respectively. Conclusions: Benznidazole treatment was safe and a large proportion of patients were able to complete a full course of benznidazole treatment under close treatment surveillance. Female sex, skin disorders and mild and moderate ADRs were independently associated with the permanent suspension of benznidazole treatment. In particular, women with moderate skin ADRs had the highest risk of benznidazole treatment interruption.
Assuntos
Doença de Chagas/tratamento farmacológico , Nitroimidazóis/efeitos adversos , Tripanossomicidas/administração & dosagem , Adulto , Bolívia/epidemiologia , Doença de Chagas/epidemiologia , Doença de Chagas/etnologia , Estudos de Coortes , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Nitroimidazóis/administração & dosagem , Nitroimidazóis/uso terapêutico , Cooperação do Paciente/etnologia , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacosRESUMO
BACKGROUND: Chagas disease is currently prevalent in European countries hosting large communities from Latin America. Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and treated accordingly is unclear. We performed an economic evaluation of systematic Chagas disease screening of the Latin American population attending primary care centres in Europe. METHODS: We constructed a decision tree model that compared the test option (screening of asymptomatic individuals, treatment, and follow-up of positive cases) with the no-test option (screening, treating, and follow-up of symptomatic individuals). The decision tree included a Markov model with five states, related to the chronic stage of the disease: indeterminate, cardiomyopathy, gastrointestinal, response to treatment, and death. The model started with a target population of 100â000 individuals, of which 4·2% (95% CI 2·2-6·8) were estimated to be infected by Trypanosoma cruzi. The primary outcome was the incremental cost-effectiveness ratio (ICER) between test and no-test options. Deterministic and probabilistic analyses (Monte Carlo simulations) were performed. FINDINGS: In the deterministic analysis, total costs referred to 100â000 individuals in the test and no-test option were 30â903â406 and 6â597â403 respectively, with a difference of 24â306â003. The respective number of quality-adjusted life-years (QALYs) gained in the test and no-test option were 61â820·82 and 57â354·42. The ICER was 5442. In the probabilistic analysis, total costs for the test and no-test option were 32â163â649 (95% CI 31â263â705-33â063â593) and 6â904â764 (6â703â258-7â106â270), respectively. The respective number of QALYs gained was 64â634·35 (95% CI 62â809·6-66â459·1) and 59â875·73 (58â191·18-61â560·28). The difference in QALYs gained between the test and no test options was 4758·62 (95% CI 4618·42-4898·82). The incremental cost-effectiveness ratio (ICER) was 6840·75 (95% CI 2545-2759) per QALY gained for a treatment efficacy of 20% and 4243 per QALY gained for treatment efficacy of 50%. Even with a reduction in Chagas disease prevalence to 0·05% and with large variations in all the parameters, the test option would still be more cost-effective than the no-test option (less than 30000 per QALY). INTERPRETATION: Screening for Chagas disease in asymptomatic Latin American adults living in Europe is a cost-effective strategy. Findings of our model provide an important element to support the implementation of T cruzi screening programmes at primary health centres in European countries hosting Latin American migrants. FUNDING: European Commission 7th Framework Program.
Assuntos
Doença de Chagas/economia , Doença de Chagas/etnologia , Emigrantes e Imigrantes/estatística & dados numéricos , Programas de Rastreamento/economia , Atenção Primária à Saúde/economia , Antiprotozoários/economia , Doença de Chagas/diagnóstico , Análise Custo-Benefício , Europa (Continente)/epidemiologia , Feminino , Humanos , América Latina/etnologia , Masculino , Programas de Rastreamento/estatística & dados numéricos , Atenção Primária à Saúde/organização & administraçãoRESUMO
BACKGROUND/METHODS: In a pioneering cross-sectional study among Bolivian immigrants in the city of São Paulo, Brazil, the epidemiological profile, clinical manifestations and morbidity of Chagas disease were described. The feasibility of the management of Chagas disease at primary healthcare clinics using a biomedical and psychosocial interdisciplinary approach was also tested. Previously, a Trypanosoma cruzi (T. cruzi) infection rate of 4.4% among 633 immigrants was reported. The samples were screened using two commercial enzyme-linked immunoassay (ELISA) tests generated with epimastigote antigens, and those with discrepant or seropositive results were analyzed by confirmatory tests: indirect immunofluorescence (IFI), TESA-blot and a commercial recombinant ELISA. PCR and blood cultures were performed in seropositive patients. RESULTS: The majority of the 28 seropositive patients were women, of whom 88.89% were of child-bearing age. The predominant clinical forms of Chagas disease were the indeterminate and atypical cardiac forms. Less than 50% received the recommended antiparasitic treatment of benznidazole. An interdisciplinary team was centered on primary healthcare physicians who applied guidelines for the management of patients. Infectologists, cardiologists, pediatricians and other specialists acted as reference professionals. Confirmatory serology and molecular biology tests, as well as echocardiography, Holter and other tests, were performed for the assessment of affected organs in secondary healthcare centers. The published high performance of two commercial ELISA tests was not confirmed. CONCLUSION: An interdisciplinary approach including antiparasitic treatment is feasible at the primary healthcare level for the management of Chagas disease in Bolivian immigrants. The itinerant feature of immigration was associated with a lack of adherence to antiparasitic treatment and was considered a main challenge for the clinical management of this population. This approach is recommended for management of the infected population in endemic and nonendemic areas, although different strategies are needed depending on the severity of the disease and the structure of the healthcare system.